Novozymes (CPSE:NSIS B) - Stock Price, News & Analysis

NSIS B Stock Overview

NSIS B fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	3/6
Financial Health	4/6
Dividends	3/6

Rewards

Earnings are forecast to grow 17.52% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Has a high level of debt

Novozymes A/S Competitors

Chr. Hansen Holding

CPSE:CHR

kr.72.3b

PPG Industries

NYSE:PPG

US$30.6b

EMS-CHEMIE HOLDING

SWX:EMSN

CHF16.6b

DuPont de Nemours

NYSE:DD

US$30.9b

Price History & Performance

Summary of all time highs, changes and price drops for Novozymes
Historical stock prices
Current Share Price	kr.388.50
52 Week High	kr.421.70
52 Week Low	kr.274.60
Beta	0.48
1 Month Change	-4.99%
3 Month Change	8.76%
1 Year Change	5.51%
3 Year Change	-12.64%
5 Year Change	25.24%
Change since IPO	1,099.07%

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 01

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Feb 14

Is Novozymes A/S (CPH:NZYM B) Worth kr.537 Based On Its Intrinsic Value?

Jan 01

We Think Novozymes (CPH:NZYM B) Can Stay On Top Of Its Debt

Nov 28

Many Would Be Envious Of Novozymes' (CPH:NZYM B) Excellent Returns On Capital

Nov 11

Is Novozymes A/S (CPH:NZYM B) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 25

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Aug 23

Shareholder Returns

	NSIS B	DK Chemicals	DK Market
7D	1.6%	1.2%	2.3%
1Y	5.5%	-1.5%	25.0%

Return vs Industry: NSIS B exceeded the Danish Chemicals industry which returned -3.3% over the past year.

Return vs Market: NSIS B underperformed the Danish Market which returned 21.5% over the past year.

Price Volatility

Is NSIS B's price volatile compared to industry and market?
NSIS B volatility
NSIS B Average Weekly Movement	3.4%
Chemicals Industry Average Movement	4.8%
Market Average Movement	4.6%
10% most volatile stocks in DK Market	9.0%
10% least volatile stocks in DK Market	2.9%

Stable Share Price: NSIS B has not had significant price volatility in the past 3 months.

Volatility Over Time: NSIS B's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1925	6,577	Ester Baiget	www.novozymes.com

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Novozymes A/S Fundamentals Summary

How do Novozymes's earnings and revenue compare to its market cap?
NSIS B fundamental statistics
Market cap	kr.180.50b
Earnings (TTM)	kr.3.02b
Revenue (TTM)	kr.17.90b

59.7x

P/E Ratio

10.1x

P/S Ratio

Is NSIS B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NSIS B income statement (TTM)
Revenue	kr.17.90b
Cost of Revenue	kr.8.18b
Gross Profit	kr.9.72b
Other Expenses	kr.6.70b
Earnings	kr.3.02b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 28, 2024

Earnings per share (EPS)	6.51
Gross Margin	54.32%
Net Profit Margin	16.89%
Debt/Equity Ratio	51.6%

How did NSIS B perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

88%

Payout Ratio

Does NSIS B pay a reliable dividends?

See NSIS B dividend history and benchmarks

When do you need to buy NSIS B by to receive an upcoming dividend?
Novozymes dividend dates
Ex Dividend Date	May 01 2024
Dividend Pay Date	May 03 2024
Days until Ex dividend	7 days
Days until Dividend pay date	9 days

Does NSIS B pay a reliable dividends?

See NSIS B dividend history and benchmarks

NSIS B Stock Overview

Rewards

Risk Analysis

Novozymes A/S Competitors

CPSE:CHR

kr.72.3b

NYSE:PPG

US$30.6b

SWX:EMSN

CHF16.6b

NYSE:DD

US$30.9b

Price History & Performance

Recent News & Updates

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Recent updates

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022